Mild Cognitive Impairment - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 83 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Mild Cognitive Impairment - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Mild Cognitive Impairment - Pipeline Review, H2 2014', provides an overview of the Mild Cognitive Impairment's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mild Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Mild Cognitive Impairment and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Mild Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mild Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Mild Cognitive Impairment Overview 8
Therapeutics Development 9
Pipeline Products for Mild Cognitive Impairment - Overview 9
Pipeline Products for Mild Cognitive Impairment - Comparative Analysis 10
Mild Cognitive Impairment - Therapeutics under Development by Companies 11
Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 13
Mild Cognitive Impairment - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Mild Cognitive Impairment - Products under Development by Companies 16
Mild Cognitive Impairment - Products under Investigation by Universities/Institutes 17
Mild Cognitive Impairment - Companies Involved in Therapeutics Development 18
Boehringer Ingelheim GmbH 18
D-Pharm Ltd. 19
Eisai Co., Ltd. 20
Eli Lilly and Company 21
FORUM Pharmaceuticals Inc. 22
Octapharma AG 23
Sage Therapeutics 24
Sanofi 25
Suven Life Sciences Ltd. 26
Theratechnologies Inc. 27
Mild Cognitive Impairment - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
BAN-2401 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
BCA-909 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CSP-1103 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
DAOI-B - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DP-NDD - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
FRM-0962 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
immune globulin (human) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ladostigil tartrate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
levetiracetam - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LY-3002813 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Peptide T - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
SAGE-547 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SAR-228810 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SUVN-901 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
SUVN-976 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SUVN-D-1108121 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SUVNG-1010034 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
tesamorelin acetate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
tropisetron hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Mild Cognitive Impairment - Recent Pipeline Updates 65
Mild Cognitive Impairment - Dormant Projects 75
Mild Cognitive Impairment - Discontinued Products 76
Mild Cognitive Impairment - Product Development Milestones 77
Featured News & Press Releases 77
Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI 77
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 78
Sep 18, 2013: EMD Serono Notifies FDA of a Shortage of Tesamorelin 78
Sep 04, 2013: Theratechnologies Provides Manufacturing Update on EGRIFTA 78
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON 79
Jul 11, 2013: Theratechnologies Obtains US Patent for Improving Cognitive Function with Tesamorelin in Patients Suffering from MCI 80
Jan 21, 2013: Theratechnologies Announces FDA Approval Of Alternative Storage Conditions For Egrifta 80
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables
Number of Products under Development for Mild Cognitive Impairment, H2 2014 9
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Mild Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H2 2014 18
Mild Cognitive Impairment - Pipeline by D-Pharm Ltd., H2 2014 19
Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2014 20
Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2014 21
Mild Cognitive Impairment - Pipeline by FORUM Pharmaceuticals Inc., H2 2014 22
Mild Cognitive Impairment - Pipeline by Octapharma AG, H2 2014 23
Mild Cognitive Impairment - Pipeline by Sage Therapeutics, H2 2014 24
Mild Cognitive Impairment - Pipeline by Sanofi, H2 2014 25
Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2014 26
Mild Cognitive Impairment - Pipeline by Theratechnologies Inc., H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Mild Cognitive Impairment Therapeutics - Recent Pipeline Updates, H2 2014 65
Mild Cognitive Impairment - Dormant Projects, H2 2014 75
Mild Cognitive Impairment - Discontinued Products, H2 2014 76